← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Chemocentryx, Inc.
Mountain View, CA
$15,487,614
Total funding
4
Grants
Funding over time
peak $3.2M · FY2005–20$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$13,987,614 · 2
FDA$1,500,000 · 2
By mechanism
U19$13,887,615 · 1
R01$1,500,000 · 2
R43$99,999 · 1
Investigators at Chemocentryx, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
CHEMOKINE ADJUVANTS FOR BIOTHREAT PATHOGEN VACCINES$3,244,665
U19 · FY2005 · AI
CHEMOKINE ADJUVANTS FOR BIOTHREAT PATHOGEN VACCINES$3,157,823
U19 · FY2006 · AI
CHEMOKINE ADJUVANTS FOR BIOTHREAT PATHOGEN VACCINES$3,124,002
U19 · FY2007 · AI
CHEMOKINE ADJUVANTS FOR BIOTHREAT PATHOGEN VACCINES$3,088,117
U19 · FY2004 · AI
CHEMOKINE ADJUVANTS FOR BIOTHREAT PATHOGEN VACCINES$1,273,008
U19 · FY2003 · AI
Phase 2 Study of Avacopan for Treatment of C3G, IND 132321, Orphan Designation 16-5590$500,000
R01 · FY2020 · FD
Phase 2 Study of Avacopan for Treatment of C3G, IND 132321, Orphan Designation 16-5590$500,000
R01 · FY2019 · FD
Phase 2 Studies of CCX168 for Treatment of ANCA-Vasculitis IND120784, OD14-4320$500,000
R01 · FY2016 · FD
A CMV vaccine with modified immuno-modulatory properties$99,999
R43 · FY2001 · AI